Disease models for the development of therapies for lysosomal storage diseases. Issue 1 (4th May 2016)

• Record Type: Journal Article
• Authors: Xu, Miao; Motabar, Omid; Ferrer, Marc; Marugan, Juan J.; Zheng, Wei; Ottinger, Elizabeth A.
• Is Part Of: Annals of the New York Academy of Sciences. Volume 1371:Issue 1(2016)
• Page Start: 15
• Page End: 29
• Publication Date: 2016-05-04
• Subjects: lysosomal storage diseases -- therapeutic development -- cell‐based disease model -- induced pluripotent stem cells -- animal models; Medical sciences -- Periodicals; Medicine -- Periodicals; Science -- Periodicals; 610
• DOI: 10.1111/nyas.13052
• Languages: English
• ISSNs: 0077-8923

Abstract

Abstract : Lysosomal storage diseases (LSDs) are a group of rare diseases in which the function of the lysosome is disrupted by the accumulation of macromolecules. The complexity underlying the pathogenesis of LSDs and the small, often pediatric, population of patients make the development of therapies for these diseases challenging. Current treatments are only available for a small subset of LSDs and have not been effective at treating neurological symptoms. Disease‐relevant cellular and animal models with high clinical predictability are critical for the discovery and development of new treatments for LSDs. In this paper, we review how LSD patient primary cells and induced pluripotent stem cell–derived cellular models are providing novel assay systems in which phenotypes are more similar to those of the human LSD physiology. Furthermore, larger animal disease models are providing additional tools for evaluation of the efficacy of drug candidates. Early predictors of efficacy and better understanding of disease biology can significantly affect the translational process by focusing efforts on those therapies with the higher probability of success, thus decreasing overall time and cost spent in clinical development and increasing the overall positive outcomes in clinical trials.